systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-305Research ArticleМЕТАБОЛИЧЕСКИЕ НАРУШЕНИЯMETABOLIC DISTURBANCESКоррекция дислипидемий при сопутствующей артериальной гипертонии с позиций обновленной парадигмы сердечно-сосудистого рискаГуревичВ. С.noemail@neicon.ruФГБОУ ВПО Санкт-Петербургский государственный университет; Центр атеросклероза и нарушений липидного обмена Клинической больницы №122 им. Л.Г.Соколова ФМБА России, Санкт-ПетербургRussian Federation2013231220221035459Copyright © Гуревич В.С., 20222022Гуревич В.С.Гуревич В.С.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/305

Обзор посвящен особенностям комбинированной терапии дислипидемии и артериальной гипертонии с учетом новой оценки уровней сердечно-сосудистого риска, изложенной в европейских и российских рекомендациях 2011–2012 гг. Рассматриваются современные представления о синергетических взаимоотношениях между дислипидемией и артериальной гипертензией. Приводятся данные клинических исследований, посвященных изучению эффективности комбинированного применения амлодипина и аторвастатина у пациентов с дислипидемией и артериальной гипертонией. Обсуждаются результаты использования фиксированных комбинаций этих препаратов с целью улучшения приверженности пациентов лечению.

дислипидемияартериальная гипертониякомбинированная терапияаторвастатинамлодипинприверженность терапииReferencesEmberson J, Whincup P, Morris R, Walker M et al. Evaluating the impact of population and high - risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004; 25: 484–91.Emberson J, Whincup P, Morris R, Walker M et al. Evaluating the impact of population and high - risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004; 25: 484–91.Catapano A.L, Reiner Z, De Backer G et al. European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217: 3–46.Catapano A.L, Reiner Z, De Backer G et al. European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217: 3–46.Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. V пересмотр. Атеросклероз и дислипидемии. 2012; 4: 5–52.Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. V пересмотр. Атеросклероз и дислипидемии. 2012; 4: 5–52.Folsom A.R. Classical and novel biomarkers for cardiovascular risk prediction in the United States. J Epidemiol 2013; 23: 158–62.Folsom A.R. Classical and novel biomarkers for cardiovascular risk prediction in the United States. J Epidemiol 2013; 23: 158–62.Kannel W.B, Dauber T.R, Friedman G.D et al. Risk factors in coronary heart disease. An evaluation of several lipids as predictors of coronary heart disease; the Framingem study. Ann Intern Med 1964; 61: 88–9.Kannel W.B, Dauber T.R, Friedman G.D et al. Risk factors in coronary heart disease. An evaluation of several lipids as predictors of coronary heart disease; the Framingem study. Ann Intern Med 1964; 61: 88–9.Borghi C, Veronesi M, Prandin M.G et al. Statins and blood pressure regulation. Curr Hypertens Rep 2001; 3: 281–8.Borghi C, Veronesi M, Prandin M.G et al. Statins and blood pressure regulation. Curr Hypertens Rep 2001; 3: 281–8.Trottier D.J, Kochar M.S. Hypertension and high cholesterol: a dangerous synergy. Am J Nurs 1992; 92: 40–3.Trottier D.J, Kochar M.S. Hypertension and high cholesterol: a dangerous synergy. Am J Nurs 1992; 92: 40–3.Borghi C, Prandin M.G, Costa F.V et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000; 35: 549–55.Borghi C, Prandin M.G, Costa F.V et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000; 35: 549–55.Stancu C.S, Toma L, Sima A.V. Dual role of lipoproteins in endothelial cell dysfunction in atherosclerosis. Cell Tissue Res 2012; 349: 433–46.Stancu C.S, Toma L, Sima A.V. Dual role of lipoproteins in endothelial cell dysfunction in atherosclerosis. Cell Tissue Res 2012; 349: 433–46.Judkins C.P, Diep H, Broughton B.R et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice. Am J Physiol Heart Circ Physiol 2010; 298: H24–32.Judkins C.P, Diep H, Broughton B.R et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice. Am J Physiol Heart Circ Physiol 2010; 298: H24–32.Koniari I, Mavrilas D, Papadaki H et al. Structural and biochemical alterations in rabbit thoracic aorta are associated with the progression of atherosclerosis. Lipids in Health and Disease 2011; 10: 125–34.Koniari I, Mavrilas D, Papadaki H et al. Structural and biochemical alterations in rabbit thoracic aorta are associated with the progression of atherosclerosis. Lipids in Health and Disease 2011; 10: 125–34.de Korte C.L, Pasterkamp G, van der Steen A.F et al. Characterization of plaque components with intravascular ultrasound elastography in human femoral and coronary arteries in vitro. Circulation 2000; 102: 617–23.de Korte C.L, Pasterkamp G, van der Steen A.F et al. Characterization of plaque components with intravascular ultrasound elastography in human femoral and coronary arteries in vitro. Circulation 2000; 102: 617–23.Aggoun Ya, Bonnet D, Sidi D et al. Arterial mechanical changes in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 2070–5.Aggoun Ya, Bonnet D, Sidi D et al. Arterial mechanical changes in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 2070–5.Laurent S, Boutouyrie P. Arterial stiffness: a new surrogate end point for cardiovascular disease? J Nephrol 2007; 20 (Suppl. 12): S45–50.Laurent S, Boutouyrie P. Arterial stiffness: a new surrogate end point for cardiovascular disease? J Nephrol 2007; 20 (Suppl. 12): S45–50.Sachidanandam K, Hutchinson J.R, Elgebaly M.M et al. Differential effects of diet - induced dyslipidemia and hyperglycemia on mesenteric resistance artery structure and function in type 2 diabetes. J Pharmacol Exp Ther 2009; 328: 123–30.Sachidanandam K, Hutchinson J.R, Elgebaly M.M et al. Differential effects of diet - induced dyslipidemia and hyperglycemia on mesenteric resistance artery structure and function in type 2 diabetes. J Pharmacol Exp Ther 2009; 328: 123–30.Igase M, Kohara K, Tabara Y et al. Low - dose rosuvastatin improves the functional and morphological markers of atherosclerosis in asymptomatic postmenopausal women with dyslipidemia. Menopause 2012; 19: 1294–9.Igase M, Kohara K, Tabara Y et al. Low - dose rosuvastatin improves the functional and morphological markers of atherosclerosis in asymptomatic postmenopausal women with dyslipidemia. Menopause 2012; 19: 1294–9.Stehouwer C.D, Henry R.M, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 2008; 51: 527–39.Stehouwer C.D, Henry R.M, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia 2008; 51: 527–39.Stokes K.Y, Granger D.N. The microcirculation: a motor for the systemic inflammatory response and large vessel disease induced by hypercholesterolaemia? J Physiol 2005; 562 (Pt 3): 647–53.Stokes K.Y, Granger D.N. The microcirculation: a motor for the systemic inflammatory response and large vessel disease induced by hypercholesterolaemia? J Physiol 2005; 562 (Pt 3): 647–53.Meyer G, Merval R, Tedgui A. Effects of pressure - induced stretch and convection on low - density lipoprotein and albumin uptake in the rabbit aortic wall. Circulation Res 1996; 79: 532–40.Meyer G, Merval R, Tedgui A. Effects of pressure - induced stretch and convection on low - density lipoprotein and albumin uptake in the rabbit aortic wall. Circulation Res 1996; 79: 532–40.Wu C.H, Chi G.C, Jerng J.S et al. Transendothelial macromolecular transport in the aorta of spontaneously hypertensive rats. Hypertension 1990; 16: 154–61.Wu C.H, Chi G.C, Jerng J.S et al. Transendothelial macromolecular transport in the aorta of spontaneously hypertensive rats. Hypertension 1990; 16: 154–61.Sun N, Wood N.B, Hughes A.D et al. Effects of transmural pressure and shear stress on LDL accumulation in the arterial wall: a numerical study using a multilayered model. Am J Physiol Heart Circ Phisiol 2007; 292: H3148–57.Sun N, Wood N.B, Hughes A.D et al. Effects of transmural pressure and shear stress on LDL accumulation in the arterial wall: a numerical study using a multilayered model. Am J Physiol Heart Circ Phisiol 2007; 292: H3148–57.Sever P, Dahlöf B, Poulter N et al. ASCOT Steering Committee Members. Potential synergy between lipid - lowering and blood - pressure - lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27: 2982–8.Sever P, Dahlöf B, Poulter N et al. ASCOT Steering Committee Members. Potential synergy between lipid - lowering and blood - pressure - lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27: 2982–8.Blank R, La Salle J, Reeves R, Maroni J et al. Single - pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). J Clin Hypertens (Greenwich) 2005; 7: 264–73.Blank R, La Salle J, Reeves R, Maroni J et al. Single - pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). J Clin Hypertens (Greenwich) 2005; 7: 264–73.Erdine S, Ro Y.M, Tse H.F et al. Gemini-AALA Investigators. Single - pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). J Hum Hypertens 2009; 23: 196–10.Erdine S, Ro Y.M, Tse H.F et al. Gemini-AALA Investigators. Single - pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). J Hum Hypertens 2009; 23: 196–10.Messerli F.H, Bakris G.L, Ferrera D et al. AVALON Investigators. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich) 2006; 8: 571–81.Messerli F.H, Bakris G.L, Ferrera D et al. AVALON Investigators. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich) 2006; 8: 571–81.Cohn J.N, Wilson D.J, Neutel J et al. Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am J Hypertens 2009; 22: 137–44.Cohn J.N, Wilson D.J, Neutel J et al. Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am J Hypertens 2009; 22: 137–44.Preston R.A, Harvey P, Herfert O et al. A randomized, placebo - controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. J Clin Pharmacol 2007; 47: 1555–69.Preston R.A, Harvey P, Herfert O et al. A randomized, placebo - controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. J Clin Pharmacol 2007; 47: 1555–69.Hobbs F.D, Gensini G, Mancini G.B et al. JEWEL Study Group. International open - label studies to assess the efficacy and safety of single - pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country - specific guidelines: the JEWEL programme. Eur J Cardiovasc Prev Rehabil 2009; 16: 472–80.Hobbs F.D, Gensini G, Mancini G.B et al. JEWEL Study Group. International open - label studies to assess the efficacy and safety of single - pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country - specific guidelines: the JEWEL programme. Eur J Cardiovasc Prev Rehabil 2009; 16: 472–80.Hobbs F.D, Gensini G, Mancini G.B et al. JEWEL Study Group. Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open - label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). Int J Cardiol 2006; 110: 242–50.Hobbs F.D, Gensini G, Mancini G.B et al. JEWEL Study Group. Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open - label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). Int J Cardiol 2006; 110: 242–50.Hradec J, Zamorano J, Sutradhar S. Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long - term risk (CRUCIAL) trial. Curr Med Res Opin 2013; 29: 589–9.Hradec J, Zamorano J, Sutradhar S. Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long - term risk (CRUCIAL) trial. Curr Med Res Opin 2013; 29: 589–9.Zamorano J, Erdine S, Lopez A.P et al. CRUCIAL Investigators. Design and rationale of a real - life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study. Postgrad Med 2010; 122: 7–15.Zamorano J, Erdine S, Lopez A.P et al. CRUCIAL Investigators. Design and rationale of a real - life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study. Postgrad Med 2010; 122: 7–15.Abdel-Zaher A.O, Elkoussi A.E, Abudahab L.H et al. Simvastatin enhances the antihypertensive effect of ramipril in hypertensive hypercholesterolemic animals and patients. Possible role of nitric oxide, oxidative stress, and high sensitivity C-reactive protein. Fundam Clin Pharmacol 2012; 26: 701–10.Abdel-Zaher A.O, Elkoussi A.E, Abudahab L.H et al. Simvastatin enhances the antihypertensive effect of ramipril in hypertensive hypercholesterolemic animals and patients. Possible role of nitric oxide, oxidative stress, and high sensitivity C-reactive protein. Fundam Clin Pharmacol 2012; 26: 701–10.Rajagopalan S, Zannad F, Radauceanu A et al. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am J Cardiol 2007; 100: 222–6.Rajagopalan S, Zannad F, Radauceanu A et al. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am J Cardiol 2007; 100: 222–6.Koh K.K, Quon M.J, Han S.H et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687–92.Koh K.K, Quon M.J, Han S.H et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687–92.Watanabe H, Kosuge K, Nishio S et al. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci 2004; 76: 281–92.Watanabe H, Kosuge K, Nishio S et al. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci 2004; 76: 281–92.Weiand D, Thoulass J, Smith W.C. Assessing and improving adherence with multidrug therapy. Lepr Rev 2012; 83: 282–91.Weiand D, Thoulass J, Smith W.C. Assessing and improving adherence with multidrug therapy. Lepr Rev 2012; 83: 282–91.Mahler C, Hermann K, Horne R, et al. Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. J Eval Clin Pract 2010; 16: 574–79.Mahler C, Hermann K, Horne R, et al. Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. J Eval Clin Pract 2010; 16: 574–79.Erdine S, Arslan E. Monitoring treatment adherence in hypertension. Curr Hypertens Rep 2013; 15: 269–72.Erdine S, Arslan E. Monitoring treatment adherence in hypertension. Curr Hypertens Rep 2013; 15: 269–72.Maningat P, Gordon B.R, Breslow J.L. How do we improve patient compliance and adherence to long - term statin therapy? Curr Atheroscler Rep 2013; 15: 291.Maningat P, Gordon B.R, Breslow J.L. How do we improve patient compliance and adherence to long - term statin therapy? Curr Atheroscler Rep 2013; 15: 291.Maddox T.M, Ho P.M. Medication adherence and the patient with coronary artery disease: challenges for the practitioner. Curr Opin Cardiol 2009; 24: 468–72.Maddox T.M, Ho P.M. Medication adherence and the patient with coronary artery disease: challenges for the practitioner. Curr Opin Cardiol 2009; 24: 468–72.Stang D, Kriston L, von Wolff A et al. Reducing cardiovascular medication complexity in a German university hospital: effects of a structured pharmaceutical management intervention on adherence. JMCP 2013; 19: 396–407.Stang D, Kriston L, von Wolff A et al. Reducing cardiovascular medication complexity in a German university hospital: effects of a structured pharmaceutical management intervention on adherence. JMCP 2013; 19: 396–407.Wilson S.A, Sanford A. Amlodipin/Atorvastatin (Caduet) for preventing heart disease. Am Fam Physician 2006; 15: 1067–68.Wilson S.A, Sanford A. Amlodipin/Atorvastatin (Caduet) for preventing heart disease. Am Fam Physician 2006; 15: 1067–68.Neutel J.M, Bestermann W.H, Dyess E.M et al. The use of a single - pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo - controlled, multicenter study. J Clin Hypertens (Greenwich) 2009; 11: 22–30.Neutel J.M, Bestermann W.H, Dyess E.M et al. The use of a single - pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo - controlled, multicenter study. J Clin Hypertens (Greenwich) 2009; 11: 22–30.

The authors declare that there are no conflicts of interest present.